Dr. Shimon Gross reports

DIAGNOSTEAR ADVANCES UK MARKET ENTRY THROUGH COMMERCIAL COLLABORATION WITH HANSON MEDICAL

Diagnostear Technologies Inc. has entered into a letter of intent (LOI) with Hanson Instruments Ltd. (trading as Hanson Medical), a United Kingdom-based supplier of ophthalmic and optometric equipment, to exclusively explore a commercial partnership for the TeaRx dry-eye Diagnostic platform in the U.K. until May 15, 2026 (the LOI period).

Hanson Medical is a well-established and respected supplier of instrumentation for optometrists and ophthalmologists. Founded in 1996, the company supports a broad customer base across the U.K., Europe and the United States, combining quality equipment with dependable service and technical support. The LOI establishes a framework under which Hanson Medical will conduct market evaluation activities and engage with eye-care professionals across the United Kingdom to assess clinical integration, commercial demand and adoption pathways for TeaRx. The initiative represents an important step in Diagnostear's strategy to build localized partnerships in key European markets.

TeaRx is a CE-IVD-approved, rapid Diagnostic solution designed for use at the point of care. By analyzing tear fluid directly during the patient visit, the system provides clinicians with objective data to support the diagnosis and management of dry eye disease, reducing reliance on the use of multiple complex techniques that often their results to do not associate with each other, and enabling faster clinical decision making.

During the LOI period, the parties intend to collaborate to determine the most effective route to commercialization in the U.K., including defining distribution responsibilities, pricing considerations and clinical engagement programs. The outcome of this process may lead to a subsequent definitive commercial agreement, subject to the results of the LOI period and mutual approval by both companies.

"The United Kingdom is a sophisticated ophthalmic market with strong clinical infrastructure and early adoption of innovative Diagnostic technologies," said Dr. Shimon Gross, chief executive officer of Diagnostear. "Working with an established local partner such as Hanson Medical allows us to assess real-world workflow integration while laying the groundwork for long-term market development."

Diagnostear continues to expand its international commercial footprint through partnerships that combine local market expertise with the company's tear-based Diagnostic platform. The U.K. initiative is intended to support broader European growth and strengthen the company's position in point-of-care ocular Diagnostics.

About Diagnostear Technologies Inc.

Diagnostear Technologies is a leader in the development of rapid, point-of-care Diagnostics for ocular diseases. The company develops multiparametric tests that provide fast, clinically actionable insights based on tear-fluid analysis. Diagnostear's mission is to transform ophthalmic care with accessible Diagnostics that support precise, data-driven decision making.

We seek Safe Harbor.